DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, diadannounced its team is presenting at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. DELFI is showcasing its groundbreaking DELFI-TF technology for treatment response monitoring alongside its early detection capabilities.
"Our presentations at AACR highlight how DELFI's fragmentomics platform is transforming both early cancer detection and treatment monitoring," said Victor E. Velculescu, MD, PhD, DELFI Diagnostics Founder and Board Director. "The DELFI technology represents a paradigm shift in how we detect cancer by combining genome-wide fragmentomics of DNA in the blood with AI algorithms for high sensitivity in the screening setting as well as for noninvasively measuring treatment efficacy in advanced cancer patients. "
DELFI is presenting multiple podium and poster sessions at AACR, including:
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection presented by Victor E. Velculescu, MD, PhD
Leveraging the cfDNA fragmentome to predict immunotherapy response presented by Valsamo Anagnostou, MD, PhD
Analysis of lung cancer clinical characteristics using cell-free DNA fragmentomes presented by Lorenzo Rinaldi, PhD
Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study presented by Denise E. Van Steijn
DELFI Diagnostics has clinically validated FirstLook Lung, its blood test designed to improve early detection of lung cancer, which remains the leading cause of cancer deaths in the United States. At the AACR Annual Meeting, DELFI will present research data on early detection in additional cancer types, including liver, ovarian, and other cancers.
In addition to the company's early detection efforts, DELFI launched the DELFI-TF* research service in February 2024. DELFI-TF actively guides critical oncology drug development decisions at five top 20 pharmaceutical companies. The technology is designed to deliver critical insights at every stage of the metastatic cancer journey, from baseline assessment and response monitoring to resistance detection and continuous insight across all treatment lines. Requiring just 800µl of plasma, DELFI-TF offers a mutation-independent monitoring solution with a 99% success rate and results typically available in 10-14 business days.
DELFI-TF's performance has been validated through clinical studies across multiple cancers, including colorectal, lung, pancreatic, breast, melanoma, and head and neck. It has demonstrated its ability to quantify tumor burden without requiring mutation profiling. This strongly correlates with Mutant Allele Frequency (MAF) measurements even when specific mutations are undetectable.
"Lack of efficacy is still the most common reason for Oncology Phase II clinical trials to fail during development, demonstrating the need for improved methods for detection of efficacy of new medical entities in early clinical trials," said Nicholas C. Dracopoli, PhD, Chief Scientific Officer and Co-Founder. "DELFI-TF offers pharmaceutical developers a streamlined, cost-effective solution for monitoring treatment response earlier and more efficiently than traditional methods."
To learn more about DELFI Diagnostics and its innovative fragmentomics platform, visit them at AACR Booth #2060 or visit www.delfidiagnostics.com.
